Abstract | BACKGROUND: METHODS: A randomized clinical trial was performed on two groups of full-term jaundiced neonates: the clofibrate-treated group ( n = 30) and the control group ( n = 30). Infants in the clofibrate group received a single oral dose of 100 mg/kg clofibrate while the neonates in the control group received distilled water (same color and volume); both groups received phototherapy. Serum total and direct bilirubin levels were measured at the beginning, 16, 24, 48, and 74 hours, after the start of the trial. RESULTS: The mean+/-SD total serum bilirubin level of the control and clofibrate groups at enrollment was 17.5+/-2.3 and 18.2+/-1.9 mg/dL, respectively (P = 0.199). The mean+/-SD total serum bilirubin in the control and clofibrate groups after 48 hours was 11.4+/-2.4 and 10.1+/-2.4 mg/dL, respectively (P = 0.047). After 72 hours of intervention, 25 (83%) neonates of the clofibrate group and 16 (53%) of the control group were discharged with a total serum bilirubin of <10 mg/dL (P = 0.026). No side-effect was observed on serial examination during hospitalization, and on the first and seventh day after discharge. CONCLUSION:
Clofibrate results in a faster decline in TSB, shorter duration of hospitalization and had no side effects in jaundiced full-term neonates.
|
Authors | Yadollah Zahedpasha, Mousa Ahmadpour-Kacho, Mahmood Hajiahmadi, Salma Naderi |
Journal | Archives of Iranian medicine
(Arch Iran Med)
Vol. 10
Issue 3
Pg. 349-53
(Jul 2007)
ISSN: 1029-2977 [Print] Iran |
PMID | 17604473
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hypolipidemic Agents
- Clofibrate
- Bilirubin
|
Topics |
- Administration, Oral
- Bilirubin
(blood)
- Clofibrate
(administration & dosage, therapeutic use)
- Combined Modality Therapy
- Female
- Humans
- Hypolipidemic Agents
(administration & dosage, therapeutic use)
- Infant, Newborn
- Jaundice, Neonatal
(blood, therapy)
- Length of Stay
- Male
- Phototherapy
- Treatment Outcome
|